Xencor Inc. Aktie
Xencor Inc. Aktie
Was spricht für und gegen Xencor Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Xencor Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Xencor Inc. | 2,23 % | 8,72 % | -6,03 % | -23,98 % | -9,22 % | -46,42 % | - |
Ironwood Pharmaceuticals | 0,69 % | -3,33 % | -8,81 % | -22,04 % | -28,92 % | -21,62 % | - |
Sage Therapeutics Inc. | -3,52 % | -3,67 % | -23,73 % | -70,21 % | -38,93 % | -81,16 % | - |
Novocure Ltd | 8,24 % | 15,96 % | -1,20 % | -77,60 % | -7,39 % | -92,22 % | - |
Kommentare
News
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for